Almost exactly a year after AstraZeneca plc quit its deal with NicOx SA for COX-inhibiting nitric oxide-donating (CINOD) drugs, NicOx said it expects to net about €24 million (US$29.8 million) through a private placement that will be used mainly to advance a lead compound from that program. (BioWorld International)

On the heels of raising $44 million in a Series C Round, MediciNova Inc. filed with the SEC to raise $100 million in an initial public offering in Japan, where it was founded four years ago as a subsidiary of Tanabe Seiyaku Co. Ltd., of Osaka. (BioWorld Today)